Nurix Therapeutics, Inc.
NRIXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of. The $2.77B market capitalization puts NRIX squarely in mid-cap range for its industry. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Market Cap
$2.77B
Beta
1.82
P/E (TTM)
10.43
P/E (Fwd)
-19.87
EPS (TTM)
$2.43
EPS (Fwd)
$-1.28
ROE
44.0%
ROA
21.1%
Cash
$1.05B
Total Debt
$65.3M
Free CF
$233.3M
52W Change
128.5%
Annual Financials
Cash vs Debt
Where NRIX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, NRIX finished 17.86% above its 150-day moving average ($20.72) and 23.40% above its 200-day moving average ($19.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NRIX overbought or oversold?
At the October 19, 2026 close, NRIX's RSI(14) was 56.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.05B in cash comfortably exceeding the $65.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $233.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 44.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 21.1% further supports the picture of efficient asset utilization. Revenue has grown from $38.6M (2022) to $84.0M (2025), reflecting a 117% increase over the period.
Nurix Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nurix Therapeutics, Inc.'s trajectory.